









Markets
/
Stocks
/
nasdaq-mdxg
/

MiMedx Group Inc

MDXG

7.150USD

+0.210+3.03%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.06BMarket Cap

32.87P/E TTM



MiMedx Group Inc

7.150

+0.210+3.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

5 / 507

Overall Ranking

61 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

12.200

Target Price

+75.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 30.26% year-on-year.

Overvalued

The company’s latest PE is 31.76, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 106.45M shares, decreasing 3.61% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.93M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 9.30, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 98.61M, representing a year-over-year increase of 13.07%, while its net profit experienced a year-over-year increase of 45.43%.

Score

Industry at a Glance

Previous score

9.30

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 8.18, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 31.76, which is -37.95% below the recent high of 19.71 and 135.83% above the recent low of -11.38.

Score

Industry at a Glance

Previous score

7.38

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for MiMedx Group Inc is 12.00, with a high of 13.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

12.200

Target Price

+75.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

MiMedx Group Inc

MDXG

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.38, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 7.28 and the support level at 6.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.61

Change

-0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.041

Neutral

RSI(14)

53.779

Neutral

STOCH(KDJ)(9,3,3)

55.498

Buy

ATR(14)

0.194

High Vlolatility

CCI(14)

36.487

Neutral

Williams %R

22.727

Buy

TRIX(12,20)

-0.029

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

6.994

Buy

MA10

7.043

Buy

MA20

7.092

Buy

MA50

6.988

Buy

MA100

6.760

Buy

MA200

7.546

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 71.95%, representing a quarter-over-quarter decrease of 0.62%. The largest institutional shareholder is The Vanguard, holding a total of 6.93M shares, representing 4.69% of shares outstanding, with 3.05% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

EW Healthcare Partners

28.20M

BlackRock Institutional Trust Company, N.A.

8.58M

+2.14%

Trigran Investments, Inc.

7.60M

-0.29%

The Vanguard Group, Inc.

Star Investors

6.69M

+0.08%

Paradigm Capital Management, Inc.

4.68M

-0.06%

State Street Global Advisors (US)

3.46M

+5.79%

Geode Capital Management, L.L.C.

2.91M

+4.79%

Dimensional Fund Advisors, L.P.

2.01M

+11.47%

Renaissance Technologies LLC

Star Investors

1.93M

+6.97%

Cannell Capital, LLC

2.13M

-41.39%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 4.21, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.74. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.